Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2017

View Archived Issues

BTK inhibitors presented by Corvus Pharmaceuticals

Safety and tolerability good with AZD-8871 in first-in-human study

Lutathera approved in Europe

FDA approves Novo Nordisk's Fiasp

KLF2 gene mutation linked to heritable pulmonary arterial hypertension

CSIR describes novel anticancer podophyllotoxin derivatives

CTxT Pty identifies new protein arginine N-methyltransferase 5 inhibitors

COLEC11, a possible therapeutic target for treating renal ischemia reperfusion injury

Japanese authorities approve Vizamyl for diagnosis of Alzheimer's

The University of Texas patents PTP-2C inhibitors

LRRK2 inhibitors reported in Denali Therapeutics patent

AstraZeneca presents new PI3Kgamma inhibitors

Merck & Co. discontinues development of two HCV drugs

ViaCyte obtains another CIRM grant to support development of PEC-Direct product candidate

Ruconest provides clinically meaningful relief of symptons in phase II study

MD Anderson and Pfizer collaborate to study combinations of Pfizer compounds in cancer

Valeant Pharmaceuticals completes sale of iNova Pharmaceuticals

Gene expression in blood shown to predict bronchiolitis obliterans after lung transplantation

AbbVie's A-485 potently inhibits CREB-binding protein and histone acetyltransferase p300

Radius Health enrolls first patient in phase I study of RAD-140 for breast cancer

U.K.'s MHRA grants PIM designation to Traumakine for acute respiratory distress syndrome

Takeda, Karolinska Institutet and SGC enter IBD collaboration

National Multiple Sclerosis Society supports preclinical studies of TG Therapeutics' TGR-1202

Indivior submits NDA for RBP-7000 for schizophrenia

NCI grant to support phase II trial of NVX-108 for glioblastoma multiforme

JCR seeks Japanese approval for JR-051 for Fabry disease

Zogenix reports promising topline results from first pivotal trial of ZX-008 in Dravet syndrome

Ablynx reports phase III results for caplacizumab in aTTP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...